Background: The chemotherapy regimen comprising carboplatin, vincristine, and etoposide (JOE) is commonly used to treat retinoblastoma. Carboplatin-induced ototoxicity is infrequently reported. High-frequency hearing loss may impair cochlear function and speech-in-noise recognition and elevate hearing thresholds. The aim was to assess hearing loss in retinoblastoma survivors treated with carboplatin-containing chemotherapy. Methods: This cross-sectional study was conducted at a single-center Pediatric Hematology-Oncology unit between 2021 and 2022. Survivors treated for retinoblastoma from 2011 to 2019 were enrolled. Hearing was evaluated using otoacoustic emissions, conventional pure-tone audiometry (500–8,000 Hz), and high-frequency audiometry (9,000–20,000 Hz). Results: Forty-two survivors (53 eyes; 76% intraocular, 24% extraocular) were evaluated. Median number of cycles of JOE received: 6 (IQR: 6, 9.3); cumulative carboplatin dose: 3151.5 mg/m 2 (IQR: 2213.5, 4563.5); median age at diagnosis: 32.5 months (IQR: 19, 43.5); median age at hearing assessment: 88.5 months (IQR: 19, 43.5) and median duration from diagnosis to hearing assessment: 50.5 months (IQR: 30, 78.5). High-frequency hearing loss was observed in 17 (40.5%) survivors, predominantly bilateral (65%). Two (4.8%) among the 17 also had hearing loss (40 dB) at 8000 Hz. No participant had clinically perceptible hearing loss or required hearing aids. There was a lack of association of hearing loss with age, duration from diagnosis to audiometry, weight-for-age, socioeconomic status, or cumulative carboplatin dose ( P>0.05). Conclusions: High-frequency sensorineural hearing loss was observed in 40.5% of survivors of retinoblastoma, though it was not clinically evident in any. Periodic hearing assessment is recommended to monitor the progression of hearing loss.